VeriSIMlife Secures $15 Million Series A Funding

VeriSIM Life, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, recently announced it has closed its oversubscribed $15 million Series A round. Serra Ventures participated in the round.

VeriSIM is a Serra Capital III and Serra Capital III SBIC portfolio company. VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to significantly improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market.

To view the full article, follow here.